Unrecognized pediatric and adult family members of children with acute brucellosis

Background and aim: Brucellosis is an infectious, contagious and zoonotic disease that occurs worldwide. The family members of an index case of brucellosis may be especially susceptible, due to sharing the same source of infection and similar risk factors for brucellosis. In this study, we propose to screen pediatric and adult family members of brucellosis index cases for detecting additional unrecognized infected family members. Materials and methods: 114 family members of 41 pediatric patients with brucellosis were evaluated. All family members completed a brief questionnaire and were tested by a standard tube agglutination test (STA). Results: The majority of family members (n = 96, 84.2%) were children. Among the 114 family members, 42 (36.8%) were seropositive, and 15 (35.7%) were symptomatic. The majority of the symptomatic seropositive family members (n = 12, 80%) had STA titers (≥1:640) higher than asymptomatic seropositive family members (n = 9, 33%; p = 0.004). Conclusion: The routine screening of both pediatric and adult family members of index cases is a priority in endemic areas. Using this screening approach, unrecognized family members who are seropositive for brucellosis will be identified earlier and be able to receive prompt treatment. Keywords: Brucellosis, Screening, Unrecognized, Turke

Adalimumab tedavisine iyi yanıt veren bir ailesel akdeniz ateşi olgusu

Ankilozan spondilit (AS) ailesel Akdeniz ateşi (AAA)’ne eşlik edebilir. Bu yazıda eşlik eden AS'si olan ve tümör nekroz faktör alfa (TNF-?) inhibitörü (adalimumab) tedavisiyle başarılı şekilde tedavi edilen 48 yaşında bir erkek AAA olgusu sunuldu. Hastaya TNF-? inhibitörü başlanmadan önce kolşisin ve hastalık modifiye edici ilaç (sulfasalazin ve leflunomid) tedavileri uygulandı fakat bu tedavilerle AAA atakları yeterli derecede kontrol altına alınamadı. Kolşisin tedavisiyle birlikte adalimumab uygulandığında, bir yıllık takip esnasında AS hastalık aktivitesinde düzelme sağlandı ve AAA ataklarının sıklığı ve şiddeti azaldı. Geleneksel tedavilerin etkisiz kaldığı AAA hastalarında TNF-? inhibitörlerinin bir tedavi seçeneği olabileceği düşüncesindeyiz.Ankylosing spondylitis (AS) may accompany Familial Mediterranean fever (FMF). In this article, we present a 48-year-old male FMF case with accompanying AS who was successfully treated with a tumor necrosis factoralpha (TNF-α) inhibitor (adalimumab). Colchicine and other disease modifying antirheumatic drug (sulfasalazine and leflunomide) treatments had been given before the initiation of the TNF-α inhibitor, but FMF attacks could not be adequately controlled by these treatments. When adalimumab was coadministered with colchicine, the disease activity of AS was improved and the frequency and the severity of the FMF attacks were reduced during the one-year follow-up. We conclude that TNF-α blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF

Adalimumab Tedavisine İyi Yanıt Veren Bir Ailesel Akdeniz Ateşi Olgusu

Ankilozan spondilit (AS) ailesel Akdeniz ateşi (AAA)'ne eşlik edebilir. Bu yazıda eşlik eden AS'si olan ve tümör nekroz faktör alfa (TNF-?) inhibitörü (adalimumab) tedavisiyle başarılı şekilde tedavi edilen 48 yaşında bir erkek AAA olgusu sunuldu. Hastaya TNF-? inhibitörü başlanmadan önce kolşisin ve hastalık modifiye edici ilaç (sulfasalazin ve leflunomid) tedavileri uygulandı fakat bu tedavilerle AAA atakları yeterli derecede kontrol altına alınamadı. Kolşisin tedavisiyle birlikte adalimumab uygulandığında, bir yıllık takip esnasında AS hastalık aktivitesinde düzelme sağlandı ve AAA ataklarının sıklığı ve şiddeti azaldı. Geleneksel tedavilerin etkisiz kaldığı AAA hastalarında TNF-? inhibitörlerinin bir tedavi seçeneği olabileceği düşüncesindeyiz.Ankylosing spondylitis (AS) may accompany Familial Mediterranean fever (FMF). In this article, we present a 48-year-old male FMF case with accompanying AS who was successfully treated with a tumor necrosis factor- alpha (TNF-?) inhibitor (adalimumab). Colchicine and other disease modifying antirheumatic drug (sulfasalazine and leflunomide) treatments had been given before the initiation of the TNF-? inhibitor, but FMF attacks could not be adequately controlled by these treatments. When adalimumab was coadministered with colchicine, the disease activity of AS was improved and the frequency and the severity of the FMF attacks were reduced during the one-year follow-up. We conclude that TNF-? blockers may be a therapeutic option when conventional treatment is ineffective in patients with FMF

Patient satisfaction with nursing practices about postoperative pain management: A systematic review

Objectives: The aim of this study was to investigate patient satisfaction with nursing practices regarding postoperative pain management